Our story

Making pathology data
actually useful.

Tissue Biosciences was founded on a simple conviction: the most information-dense biological signal in drug discovery is locked inside tissue — and the tools, services, and infrastructure to unlock it are years behind where they need to be.

The vision

The gap we're
building into.

Why this company exists

Pathology generates some of the richest biological signal in drug discovery. Most of it is completely inaccessible to AI. Inconsistent annotations, proprietary formats, and reports designed for human eyes rather than model training all stand in the way. The field is sitting on an enormous asset it hasn't figured out how to unlock — and the services infrastructure around pathology hasn't helped.

We offer expert pathology consultation and quantitative image analysis for drug discovery and preclinical teams — fast turnarounds, transparent pricing, and scientific partnership that actually means something. We're also developing model-ready annotated image datasets to start closing the gap between pathology data and the AI tools that need it.

The goal is simple: make exceptional pathology services accessible, and make the data those services generate actually useful.

The team

Who's behind it

Stephen Morreale

Founder & CEO

Stephen's career spans digital pathology CRO sales, preclinical CRO business development, and rare disease strategy consulting — building deep commercial fluency across the full tissue-to-data pipeline. He has built territories from the ground up, including growing a digital pathology CRO's New England business to a multi-million dollar annual run rate with biopharma accounts spanning Sanofi, Alexion, Alnylam, and Flagship Pioneering.

He founded Tissue Biosciences to close the gap between exceptional pathology services and the AI-ready data that drug discovery teams actually need.

Jack Wilson

Co-Founder, Commercial

Commercial leader working at the intersection of translational research, histopathology, and biospecimen-derived data. Jack's background spans wet-lab neuroscience, clinical diagnostics, gene delivery, and CRO and biospecimen infrastructure — giving him a rare ability to navigate both the technical and operational sides of translational workflows.

His work is focused on a problem that quietly undermines drug discovery: biospecimens that are technically collected but scientifically unusable downstream due to missing or inconsistent metadata, poor annotation, or broken study continuity.

By the numbers

Built on experience,
not promises.

40+

Years of combined pathology experience across oncology, immunology, and toxicology

1,000+

Image analysis projects delivered across drug discovery and preclinical programs

2-day

Rush turnaround available for pathology consultation and image analysis

Making pathology dataactually useful.

The gap we'rebuilding into.

Who's behind it

Built on experience,not promises.

If this resonates,let's talk.

Making pathology data
actually useful.

The gap we're
building into.

Built on experience,
not promises.

If this resonates,
let's talk.